Safety, tolerability, and metabolism of niraparib in Black women with advanced ovarian cancer

Single-Arm, Prospective, Multicenter Study Evaluating Safety, Tolerability, and Metabolism of Niraparib as Maintenance Following Front-Line Treatment for Ovarian Cancer in Women of African Ancestry

This will test whether the drug niraparib is safe, tolerable, and how it is processed in Black women who have completed initial treatment for stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.

Quick facts

• Phase: Phase 4
• Study type: Interventional
• Enrollment: 70 (estimated)
• Ages: 18 Years and up
• Sex: Female
• Sponsor: University of Miami (Academic / other)
• Drugs / interventions: chemotherapy, radiation
• Locations: 3 sites (Fort Lauderdale, Florida and 2 other locations)
• Trial ID: NCT06412120 on ClinicalTrials.gov

What this trial studies

This phase 4 interventional study gives niraparib as maintenance therapy to women who self-identify as Black and who completed adjuvant treatment for newly diagnosed stage III or IV high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. Researchers will collect blood or saliva and tumor specimens to measure germline mutations in the Fanconi Anemia pathway and to estimate degree of African ancestry and environmental factors linked to drug effects. The study focuses on safety, tolerability, and drug metabolism and aims to relate those outcomes to genetic ancestry and other characteristics. Sites include University of Miami and Broward Health in Florida and Ahmadu Bello University Teaching Hospital in Zaria, Nigeria.

Who should consider this trial

Good fit: Black women aged 18 or older who completed adjuvant treatment for newly diagnosed stage III or IV high-grade serous or high-grade endometrioid ovarian, fallopian tube, or primary peritoneal cancer and who can provide blood/saliva and tumor tissue are the intended participants.

Not a fit: People who do not identify as Black, have earlier-stage disease, non–high-grade histology, or cannot provide required biospecimens or travel to study sites are unlikely to be eligible or benefit from this study.

Why it matters

Potential benefit: If successful, this work could clarify whether Black women have different safety or metabolism profiles on niraparib and lead to more tailored dosing or monitoring for this group.

How similar studies have performed: PARP inhibitors such as niraparib have demonstrated benefit as maintenance therapy in ovarian cancer, but explicitly linking drug safety and metabolism to degree of African ancestry is a novel focus.

Eligibility criteria

Inclusion Criteria:

1. Participant must be female ≥18 years of age, able to understand study procedures, and agree to participate in the study by providing written informed consent.
2. Self-identify as Black. Please note that individuals who identify as Latino are eligible to participate so long as they also self-identify as Black.
3. Participant has completed adjuvant treatment for newly diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer according to the International Federation of Gynecology and Obstetrics staging criteria.
4. Participant must have high-grade serous or high-grade endometrioid histology.
5. Participant must provide saliva and/or blood specimens for assessment of germline mutation(s) in the Fanconi Anemia pathway.
6. Participant must provide formalin-fixed, paraffin-embedded (FFPE) or fresh tumor specimen from initial cytoreductive surgery (primary debulking) or initial pre-treatment core biopsy (if neoadjuvant chemotherapy (NACT) received; tumor obtained from interval cytoreduction acceptable if pre-treatment biopsy not obtained).
7. Participant must have had a complete or partial clinical response to adjuvant treatment as confirmed by CT scan within 8 weeks after completion of the last dose of platinum-based chemotherapy.
8. Participant must have recovered to ≤ Grade 1 in terms of toxicity from prior treatments.
9. Participant must not have any known contraindication or hypersensitivity to niraparib or any of its excipients.
10. Participants must be considered candidates for maintenance niraparib therapy by their treating physician.
11. Participants should have adequate organ function as defined below:

    * Platelets ≥ 100 platelets × 10\^9/L
    * Hemoglobin ≥ 9 g/dL or 5.6 mmol/L
    * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × upper limit of normal (ULN), \<5× in patients with known liver metastases
    * Serum total bilirubin ≤ 1.5 × ULN
    * 1.5-3.0 × ULN may be included with appropriate starting dose adjustment to 200 mg daily.
    * Creatinine \<1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥50 mL/min by Cockcroft-Gault

      * Depending on scenario, glomerular filtration rate (GFR) 30-49 mL/min can be permissible.
12. Patients with known human immunodeficiency virus (HIV) are allowed if they meet all the following criteria:

    * Cluster of differentiation 4 (CD4) ≥350/μL and viral load \<400 copies/mL
    * No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within 12 months before enrollment
    * No history of HIV-associated malignancy for the past 5 years. Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV started \>4 weeks before study enrollment.
13. A female participant is eligible to participate if she is not pregnant or breastfeeding and at least one of the following conditions applies:

    * Is not a woman of childbearing potential (WOCBP), or
    * Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year) from the Screening Visit through at least 180 days after the last dose of study treatment and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study treatment, and
    * A WOCBP must have a negative test result from a highly sensitive pregnancy test (urine or serum, as required by local regulations) within 72 hours before treatment. Additional periodic testing should be carried out according to the protocol.

    Note: The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
14. Participant must agree to complete HRQoL and patient reported outcomes (PRO) measures throughout the study period.

Exclusion Criteria:

1. Any of the following histologies: low-grade serous carcinoma, grade 1 or 2 endometrioid adenocarcinoma, clear cell, mucinous, transitional cell, carcinosarcoma, undifferentiated, dedifferentiated
2. Any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
3. Primary progressive, platinum-refractory disease
4. Participant is at an increased risk of bleeding due to concurrent conditions (eg, major injuries or major surgery within the past 28 days before start of study treatment).
5. Current diagnosis of platelet disorder (eg, thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenia (ITP))
6. Inability to swallow orally administered medication or has a gastrointestinal disorder likely to interfere with absorption of the study medication
7. Participants that have systolic blood pressure (SBP\])\>140 mmHg or diastolic blood pressure (DBP)\>90 mmHg that has not been adequately treated or controlled.
8. Active second primary malignancy
9. Participant is pregnant, currently breastfeeding an infant, or expecting to conceive children while receiving study treatment and/or for up to 180 days after the last dose of study treatment.
10. Participant has received a live vaccine within 30 days of planned start of study therapy. Coronavirus disease 2019 (COVID-19) vaccines that do not contain live viruses are allowed.
11. Participant has received a transfusion (platelets or red blood cells) or colony-stimulating factors (eg, granulocyte macrophage colony-stimulating factor or recombinant erythropoietin) within 4 weeks before the first dose of study treatment.
12. Participant has had radiotherapy encompassing \>20% of the bone marrow within 2 weeks or any radiation therapy within 1 week before Day 1 of protocol therapy.
13. Participant has leptomeningeal disease, carcinomatous meningitis, symptomatic brain metastasis, or radiographic signs of central nervous system hemorrhage.
14. Participant has current active pneumonitis or any history of pneumonitis requiring steroids (any dose) or immunomodulatory treatment within 90 days of planned start of the study.
15. Participants with active hepatitis B or C infection.
16. Patient with prior history of posterior reversible encephalopathy syndrome (PRES).
17. Patients with impaired decision-making capacity.
18. Participants have high medical risk due to a serious, uncontrolled medical disorder; non malignant systemic disease; or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, active uncontrolled coagulopathy, bleeding disorder, or any psychiatric disorder that prohibits obtaining informed consent.
19. Patient is currently receiving one or more cytotoxic, hormonal, or other medications to treat their cancer.

Where this trial is running

Fort Lauderdale, Florida and 2 other locations

• Broward Health — Fort Lauderdale, Florida, United States (Recruiting)
• University of Miami — Miami, Florida, United States (Recruiting)
• Ahmadu Bello University Teaching Hospital (ABUTH) — Zaria, Kaduna State, Nigeria (Recruiting)

Study contacts

• Principal investigator: Matthew Schlumbrecht, MD — University of Miami
• Study coordinator: Matthew Schlumbrecht, MD, MPH

Conditions Ovarian Cancer